ASCO: Merus' gene-targeting cancer drug shrinks tumors. Will execs go it alone or partner?

[cafead]

via Merus’ NRG1 gene targeting cancer treatment helped to shrink tumors and kept working for up to 9.1 months, leaving the company’s leadership with an important question: partner up or go it alone for commercialization?

article source